Biogen Idec to Report Third Quarter 2010 Financial Results on October 26, 2010

WESTON, Mass.--(BUSINESS WIRE)-- Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report third quarter 2010 financial results on Tuesday, October 26, 2010, before the financial markets open.

Following the release of the financials, the Company will host a live webcast where Biogen Idec management will discuss the financial results, at 8:30 am ET. To access the live webcast please go to Biogen Idec’s website at investor.biogenidec.com. Following the live webcast, an archived version of the call will be available at the same URL.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients worldwide benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.



CONTACT:

Biogen Idec
Karen Jewell, 781-464-2066
Investor Relations

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Professional Services  Finance

MEDIA:

Suggested Articles

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.